Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 11/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476069 | 1.00 | ADAM17 (0.48) | ADAM17SLC6A9ALDH1A1LMNATSHR | |
| SCHEMBL10276416 | 0.86 | ADAM17 (0.62) | ADAM17LMNASMN1; SMN2ADAM10MMP3 | |
| SCHEMBL10276407 | 0.86 | ADAM17 (0.62) | ADAM17LMNASMN1; SMN2ADAM10MMP3 | |
| SCHEMBL10276198 | 0.84 | ADAM17 (0.54) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL10276201 | 0.84 | ADAM17 (0.54) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL10275947 | 0.83 | ADAM17 (0.49) | ADAM17LMNAADAM10MMP3MMP1 | |
| SCHEMBL1504817 | 0.80 | ALDH1A1 (0.44) | SLC6A9ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL10276547 | 0.79 | ADAM17 (0.74) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL10475831 | 0.79 | ADAM17 (0.51) | ADAM17LMNAADAM10MMP3MMP1 | |
| SCHEMBL10475888 | 0.79 | ADAM17 (0.51) | ADAM17LMNAADAM10MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115102-B2 | N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-08-25 | — | — | US | disclosed |
| EP-2477968-B1 | N-[2-HYDROXYCARBAMOYL-2-(PIPERAZINYL)ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2477968-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | Galderma Research & Development (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011033009-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | CTSB, TPSAB1, PIGS | ADAM17 6/4885SLC6A9 4850/4885ALDH1A1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.